Safety and Tolerability of Xanthohumol in Adults With Crohn's Disease: Results of a Triple-Masked, Randomized, Placebo-Controlled Phase 2 Trial.
- 2026-03
- RCT · n = 20
- Molecular nutrition & food research 70(6)
- Ryan Bradley
- Carina A Staab
- Paige E Jamieson
- Blake O Langley
- Thomas O Metz
- Jan F Stevens
- PubMed: 41834265
- DOI: 10.1002/mnfr.70438
- High evidence
- Rigorous Journal
- Clinical
Between-group comparisons demonstrated differences for changes in BMI and gamma-glutamyltransferase (GGT), favoring XN: BMI: -0.67 (0.0, 1.3), p = 0.04 and GGT: -4.8 U/L, 95% CI 0.8-8.8, p = 0.02, which may reflect beneficial effects on hepatic and metabolic health in CD.
- Effect
- Beneficial
- Effect size
- Small
- Significant
- Yes
- Dose
- 24 mg/day